{"transactions":[{"id":4634952,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T22:49:12.000Z","date":"2026-09-22","kind":"exercise","planned":false,"acquired":false,"shares":756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.32,"expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":756},"source":{"system":"sec-edgar","filing":"0001606302-26-000007","document":"wk-form4_1790966949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000007/wk-form4_1790966949.xml","form_type":"4"}},{"id":4634951,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:49:12.000Z","date":"2026-09-22","kind":"exercise","planned":false,"acquired":true,"shares":756,"price":25.32,"value":19141.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029."}],"balance_after":1345063,"source":{"system":"sec-edgar","filing":"0001606302-26-000007","document":"wk-form4_1790966949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000007/wk-form4_1790966949.xml","form_type":"4"}},{"id":825181,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-30T21:38:25.000Z","date":"2026-03-26","kind":"sale","planned":true,"acquired":false,"shares":3352,"price":22.0749,"value":73995.0648,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On March 26, 2026, a Restricted Stock Unit (\"RSU\") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029."}],"balance_after":1344307,"source":{"system":"sec-edgar","filing":"0001606302-26-000005","document":"wk-form4_1774905414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000005/wk-form4_1774905414.xml","form_type":"4"}},{"id":884484,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-24T23:48:26.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":155100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":155100,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":155100},"source":{"system":"sec-edgar","filing":"0001606302-26-000002","document":"wk-form4_1771976903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000002/wk-form4_1771976903.xml","form_type":"4"}},{"id":884483,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-24T23:48:26.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":25900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.  Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024.  This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person."}],"balance_after":1347659,"source":{"system":"sec-edgar","filing":"0001606302-26-000002","document":"wk-form4_1771976903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000002/wk-form4_1771976903.xml","form_type":"4"}},{"id":1188761,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:27:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":143500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":143500,"derivative":{"exercise_price":16.14,"exercise_date":"2025-03-26","underlying":"Common Stock","underlying_shares":143500},"source":{"system":"sec-edgar","filing":"0001404644-25-000020","document":"wk-form4_1743211653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000020/wk-form4_1743211653.xml","form_type":"4"}},{"id":1188760,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-29T01:27:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":1274259,"source":{"system":"sec-edgar","filing":"0001404644-25-000020","document":"wk-form4_1743211653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000020/wk-form4_1743211653.xml","form_type":"4"}},{"id":1352550,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-26T02:29:04.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":47500,"price":20.4,"value":969000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":1297859,"source":{"system":"sec-edgar","filing":"0001404644-24-000112","document":"wk-form4_1732588138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000112/wk-form4_1732588138.xml","form_type":"4"}},{"id":1576492,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2024-03-15T00:54:55.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":93282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":93282,"derivative":{"exercise_price":36.06,"expiration_date":"2034-03-13","underlying":"Common Stock","underlying_shares":93282},"source":{"system":"sec-edgar","filing":"0001404644-24-000010","document":"wk-form4_1710464082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000010/wk-form4_1710464082.xml","form_type":"4"}},{"id":4191936,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-10-04T21:00:19.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":283,"price":58.8932,"value":16666.7756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":16875,"source":{"system":"sec-edgar","filing":"0001144204-17-051412","document":"v476459_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417051412/v476459_4.xml","form_type":"4"}},{"id":4245500,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-08-02T20:59:38.000Z","date":"2017-07-31","kind":"sale","acquired":false,"shares":130,"price":123.1176,"value":16005.288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":17158,"source":{"system":"sec-edgar","filing":"0001144204-17-040071","document":"v472266_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417040071/v472266_form4.xml","form_type":"4"}},{"id":4263788,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-07-05T21:00:52.000Z","date":"2017-07-03","kind":"sale","acquired":false,"shares":257,"price":121.78,"value":31297.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":17288,"source":{"system":"sec-edgar","filing":"0001144204-17-035810","document":"v470321_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417035810/v470321_form4.xml","form_type":"4"}},{"id":4334949,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-05-03T21:01:13.000Z","date":"2017-05-01","kind":"sale","acquired":false,"shares":114,"price":113.1201,"value":12895.6914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":17545,"source":{"system":"sec-edgar","filing":"0001144204-17-024325","document":"v466055_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417024325/v466055_4.xml","form_type":"4"}},{"id":4357912,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-04-05T21:01:26.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":257,"price":114.9973,"value":29554.3061,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":17659,"source":{"system":"sec-edgar","filing":"0001144204-17-019297","document":"v463649_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417019297/v463649_4.xml","form_type":"4"}},{"id":4468266,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-02-03T21:02:13.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares of common stock underlying this option will vest on January 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan."}],"balance_after":8300,"derivative":{"exercise_price":107.18,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001144204-17-006035","document":"v458369_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417006035/v458369_4.xml","form_type":"4"}},{"id":4468265,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-02-03T21:02:13.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the shares of restricted stock will vest on January 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the \"2012 Plan\"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan."}],"balance_after":17916,"source":{"system":"sec-edgar","filing":"0001144204-17-006035","document":"v458369_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417006035/v458369_4.xml","form_type":"4"}},{"id":4498142,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2017-01-05T21:00:16.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":816,"price":103.9191,"value":84797.9856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":12916,"source":{"system":"sec-edgar","filing":"0001144204-17-000938","document":"v456333_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420417000938/v456333_4.xml","form_type":"4"}},{"id":4569264,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2016-11-02T21:00:17.000Z","date":"2016-10-31","kind":"sale","acquired":false,"shares":129,"price":123.8165,"value":15972.3285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee."}],"balance_after":13732,"source":{"system":"sec-edgar","filing":"0001144204-16-131218","document":"v451999_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000114420416131218/v451999_4.xml","form_type":"4"}}]}